quecitinib (QY201) / E-nitiate Biopharma, VivaVision - LARVOL DELTA

A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis (clinicaltrials.gov) - P3 | N=154 | Active, not recruiting | Sponsor: VivaVision Biotech, Inc | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Ocular Inflammation • Ophthalmology • Uveitis

A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Non-Segmental Vitiligo (clinicaltrials.gov) - P2 | N=200 | Recruiting | Sponsor: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

New P2 trial • Dermatology • Immunology • Vitiligo

Phase IIa Study of Pharmacokinetics, Safety and Efficacy of QY201 Tablets in Adolescent Subjects With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - P2 | N=24 | Completed | Sponsor: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis. (clinicaltrials.gov) - P3 | N=460 | Enrolling by invitation | Sponsor: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

New P3 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

The Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Orally Dosed QY201, a Novel JAK1/TYK2 Inhibitor, in Chinese Healthy Subjects. (PubMed, J Clin Pharmacol) - "QY201 was generally safe and well tolerated following oral administration, with dose-limiting toxicity of the highest tested dose of 40 mg being well tolerated. The favorable PK, PD, safety, and tolerability results from these studies supported evaluations of QY201 in future clinical trials."

Clinical • Journal • PK/PD data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • CRP • JAK1 • TYK2

QY201 in adults with moderate-to-severe atopic dermatitis: 12-week results from a dose-finding phase 2 trial (AAD 2025) - No abstract available

Clinical • Late-breaking abstract • P2 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - P1/2 | N=260 | Not yet recruiting | Sponsor: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

New P1/2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology